Content developed independently by our editors and supported by our partners. The road to a medical diagnosis is not always a simple one—something Carrington Garvin, 24, discovered when she began ...

While PBC progresses slowly and many patients do not experience symptoms during the early stages of disease, there are many symptoms to look out for. In later stages of disease, patients may ...

"PBC is one of those liver diseases where you can have cirrhosis and liver failure if you don't do anything about it in a matter of 10 to 15 years," said Lucy Mathew, NP, of Cedars Sinai in Los ...

Primary biliary cholangitis (PBC) is an autoimmune disease that causes the destruction of bile ducts within the liver. The loss of bile ducts results in bile acid buildup, which causes inflammation ...

Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for Seladelpar Gilead (seladelpar lysine dihydrate) to treat primary biliary cholangitis (PBC). PBC is a chronic ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. A number of new treatments have become ...

Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. Primary sclerosing cholangitis ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...

PHOENIX — Seladelpar, a first-in-class, selective peroxisome proliferator-activated receptor delta agonist, shows significant improvement across key pruritus outcomes in patients with primary biliary ...